Literature DB >> 25559471

Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.

Michela Boi1, Emanuele Zucca, Giorgio Inghirami, Francesco Bertoni.   

Abstract

The currently used 2008 World Health Organization classification recognizes two types of systemic anaplastic large T cell lymphoma according to ALK protein expression in tumour cells. First, the 'anaplastic large cell lymphoma, ALK positive' (ALK(+) ALCL) that is characterized by the presence of ALK gene rearrangements and consequent ALK protein expression, and, second, the 'anaplastic large cell lymphoma, ALK negative' (ALK(-) ALCL) that is a provisional entity lacking ALK protein expression but cannot be distinguished morphologically from ALK(+) ALCL. In this review we summarize the current knowledge on the genetic lesions and biological features that underlie the pathogenesis of ALK(+) and the ALK(-) ALCL and that can lead to the use of targeted anti-cancer agents.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Crizotinib; JAK; PRDM1; anaplastic lymphoma kinase; lymphoma

Mesh:

Substances:

Year:  2015        PMID: 25559471     DOI: 10.1111/bjh.13265

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Authors:  Hélène Roussel; Eléonore De Guillebon; Lucie Biard; Marion Mandavit; Laure Gibault; Elisabeth Fabre; Martine Antoine; Paul Hofman; Michèle Beau-Faller; Hélène Blons; Claire Danel; Françoise Le Pimpec Barthes; Alain Gey; Clémence Granier; Marie Wislez; Pierre Laurent-Puig; Stéphane Oudard; Patrick Bruneval; Cécile Badoual; Jacques Cadranel; Eric Tartour
Journal:  Oncoimmunology       Date:  2017-02-21       Impact factor: 8.110

2.  ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.

Authors:  Leona A Doyle; Adrián Mariño-Enriquez; Christopher D M Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2015-04-10       Impact factor: 7.842

Review 3.  Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.

Authors:  Biagio Ricciuti; Andrea De Giglio; Carmen Mecca; Cataldo Arcuri; Sabrina Marini; Giulio Metro; Sara Baglivo; Angelo Sidoni; Guido Bellezza; Lucio Crinò; Rita Chiari
Journal:  Med Oncol       Date:  2018-04-17       Impact factor: 3.064

Review 4.  Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.

Authors:  Rodney R Miles; Rikin K Shah; J Kimble Frazer
Journal:  Br J Haematol       Date:  2016-03-11       Impact factor: 6.998

5.  Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.

Authors:  Nikola Ptáková; Markéta Miesbauerová; Ján Kosťun; Petr Grossmann; Henrieta Šidlová; Jaroslav Pavelka; Jiří Presl; Reza Alaghehbandan; Jiří Bouda; Ondrej Ondič
Journal:  Virchows Arch       Date:  2018-08-16       Impact factor: 4.064

6.  Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.

Authors:  Qian Zhang; Hong Y Wang; Anindita Nayak; Selene Nunez-Cruz; Artur Slupianek; Xiaobin Liu; Johnvesly Basappa; Jing-Song Fan; Seble Chekol; Reza Nejati; Agata M Bogusz; Suzanne D Turner; Kunchithapadam Swaminathan; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

Review 7.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

Review 8.  Anaplastic lymphoma kinase: Role in cancer and therapy perspective.

Authors:  Zhihong Zhao; Vivek Verma; Mutian Zhang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

9.  Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies: a single-institution study of 225 cases.

Authors:  Wen Xue; Yan Sheng; Xiangqin Weng; Yongmei Zhu; Yan Zhao; Pengpeng Xu; Xiaochun Fei; Xiaoyan Chen; Li Wang; Weili Zhao
Journal:  Front Med       Date:  2015-11-11       Impact factor: 4.592

10.  Preliminary Study: Proteomic Profiling Uncovers Potential Proteins for Biomonitoring Equine Melanocytic Neoplasm.

Authors:  Parichart Tesena; Amornthep Kingkaw; Wanwipa Vongsangnak; Surakiet Pitikarn; Narumon Phaonakrop; Sittiruk Roytrakul; Attawit Kovitvadhi
Journal:  Animals (Basel)       Date:  2021-06-27       Impact factor: 2.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.